KPRX · Kiora Pharmaceuticals Inc · Documents

Jan 31

Current report 8-K Events of Jan 25

Entered into a material agreement, Regulation FD disclosure

Jan 16

Current report 8-K

Delisting notice or listing transfer

Nov 9

Current report 8-K

Financial results

Nov 9

Current report 8-K

Regulation FD disclosure

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $5.76M Diluted EPS -$0.89

Nov 6

Current report 8-K Events of Nov 4

Current report

Sep 28

Current report 8-K Events of Sep 27

Shareholder vote results

Sep 21

Current report 8-K Events of Sep 20

Director or officer change, or executive pay, Other events

Sep 1

Current report 8-K Events of Aug 31

Other events

Sep 1

Proxy statement DEFA14A

Proxy statement

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $2.61M Diluted EPS -$0.79

Aug 1

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Jul 21

Proxy statement DEF 14A Meeting Aug 31, 2023

Proxy statement

Jul 20

Current report 8-K Events of Jul 18

Delisting notice or listing transfer

Jul 11

Proxy statement PRE 14A Meeting Aug 31, 2023

Proxy statement

Jun 21

Current report 8-K

Shareholder vote results

Jun 15

Current report 8-K Events of Jun 12

Entered into a material agreement, Other events

Jun 6

Current report 8-K Events of Jun 2

Entered into a material agreement, Charter or bylaw amendment, or fiscal year change, Other events

Jun 1

Registration statement S-1/A

Registration statement

May 12

Registration statement S-1/A

Registration statement

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $1.87M Diluted EPS -$1.00

May 5

Registration statement S-1

Registration statement

Apr 28

Proxy statement DEF 14A Meeting Jun 21, 2023

Proxy statement

Apr 27

Current report 8-K

Other events

Mar 30

Current report 8-K Events of Mar 24

Change of auditor

Mar 23

Current report 8-K

Financial results

Mar 23

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $13.58M Diluted EPS -$18.55

Feb 7

Current report 8-K

Other events

Feb 3

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Other events

Feb 3

Registration statement S-1

Registration statement

Jan 9

Current report 8-K

Regulation FD disclosure

Jan 3

Current report 8-K Events of Jan 1

Other events

Dec 22

Registration statement S-1

Registration statement

Nov 21

Current report 8-K Events of Nov 17

Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights, Other events

Nov 9

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $5.12M Diluted EPS -$6.03

Oct 13

Current report 8-K

Other events

Sep 26

Current report 8-K Events of Sep 23

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

Sep 23

Current report 8-K

Shareholder vote results

Sep 16

Current report 8-K Events of Sep 13

Director or officer change, or executive pay, Shareholder vote results, Other events

Aug 25

Current report 8-K Events of Aug 23

Delisting notice or listing transfer

Aug 15

Proxy statement DEF 14A Meeting Sep 23, 2022

Proxy statement

Aug 12

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $2.4M Diluted EPS -$0.18

Aug 8

Proxy statement DEF 14A Meeting Sep 15, 2022

Proxy statement

Aug 5

Proxy statement PRE 14A Meeting Sep 23, 2022

Proxy statement

Aug 4

Current report 8-K Events of Aug 1

Charter or bylaw amendment, or fiscal year change

Jul 27

Proxy statement PRE 14A Meeting Sep 15, 2022

Proxy statement

Jul 26

Current report 8-K Events of Jul 22

Entered into a material agreement, Charter or bylaw amendment, or fiscal year change, Other events

Jul 21

Registration statement S-1/A

Registration statement